196 related articles for article (PubMed ID: 25883396)
1. Competing for public funding of medicines to treat rare disorders in New Zealand.
Crausaz S
Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
[No Abstract] [Full Text] [Related]
2. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
3. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
Duguet C; Ferry A
Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
[No Abstract] [Full Text] [Related]
4. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
5. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
6. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
7. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
8. Companies look for profit in orphan drugs.
Thompson CA
Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
[No Abstract] [Full Text] [Related]
9. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
Rawson NSB
J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
[TBL] [Abstract][Full Text] [Related]
10. Rare diseases and effective treatments: are we delivering?
Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
[No Abstract] [Full Text] [Related]
11. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
Lee J
Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
[No Abstract] [Full Text] [Related]
12. Pfizer explores rare disease path.
Shaffer C
Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
[No Abstract] [Full Text] [Related]
13. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
[TBL] [Abstract][Full Text] [Related]
14. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
15. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
Dear JW; Lilitkarntakul P; Webb DJ
Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
[TBL] [Abstract][Full Text] [Related]
16. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
17. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
18. Rationing of drugs for rare diseases.
Hughes D
Pharmacoeconomics; 2006; 24(4):315-6. PubMed ID: 16605277
[No Abstract] [Full Text] [Related]
19. Reducing the cost of rare disease drugs.
Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156
[No Abstract] [Full Text] [Related]
20. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
Mentzakis E; Stefanowska P; Hurley J
Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]